What is ACHFF stock price today?

ACHFF (Arch Biopartners Inc) stock is trading at $0.93 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ACHFF stock going up or down today?

ACHFF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ACHFF stock now?

The decision to buy ACHFF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ACHFF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ACHFF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ACHFF stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ACHFF is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ACHFF's P/E ratio?

P/E ratio data for ACHFF will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ACHFF's market cap?

ACHFF (Arch Biopartners Inc) has a market capitalization of $0.07 billion, making it a small-cap stock.

What is ACHFF's price to book ratio?

Price-to-book ratio for ACHFF is available on our dashboard along with other valuation metrics.

Does ACHFF pay dividends?

ACHFF does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ACHFF's dividend yield?

ACHFF does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ACHFF stock a good long-term investment?

ACHFF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ACHFF's revenue growth rate?

ACHFF has shown revenue growth of -0.6% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ACHFF are available on our dashboard with complete income statement analysis.

What are the risks of investing in ACHFF?

Key risks for ACHFF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ACHFF compare to its competitors?

Compare ACHFF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ACHFF's performance and positioning.

What is ACHFF's stock price target for 2026?

Our AI model provides price targets for ACHFF based on fundamental analysis: Bull case $1.21 (+30%), Base case $1.07 (+15%), Bear case $0.84 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ACHFF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ACHFF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ACHFF's next earnings report?

ACHFF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ACHFF - Arch Biopartners Inc

NYSE * Healthcare * Biotechnology

$0.93

$-0.06 (-6.06%)

About Arch Biopartners Inc

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops AB569 for treating antibiotic-resistant bacterial infections and as a topical treatment for wounds; and Borg, a peptide-solid surface interface, which are binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Arch Biopartners Inc. is based in Toronto, Canada.

ACHFF Key Statistics

Market Cap

$66.47M

EPS

$-0.02

Revenue Growth

-0.6%

How ACHFF Compares to Peers

ACHFF is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ACHFF(This stock)	$66.47M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.12B	15.0	0%	0.2%	vs BIIB

Arch Biopartners Inc Company Information

Headquarters: 545 King Street West, Toronto, ON, Canada, M5V 1M1, undefined
Website: www.archbiopartners.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: January 20, 2026 at 10:10 PM EST

Ready to invest in ACHFF?

Commission-free trading available. Affiliate links.

Upcoming Events for ACHFF

Dashboard

Enter a ticker to analyze